UnitedHealth Group Incorporated (UNH) AI Stock Analysis

UnitedHealth Group Incorporated operates primarily in the United States across four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. UnitedHealthcare provides health benefit plans and services to national employers, public sector entities, mid-sized and small businesses, and individuals, including Medicaid, Medicare coverage for individuals over 50, and children's health insurance. OptumHealth delivers care provider networks, care delivery solutions, health management, and financial services. OptumInsight supplies software, information products, advisory consulting, and managed services outsourcing to hospital systems, physicians, health plans, and life sciences companies. OptumRx provides pharmacy care services, including retail network contracting and home delivery.

UnitedHealth Group increased revenue from $287.60B in FY2021 to $447.57B in FY2025, producing a 5-year revenue compound annual growth rate of 11.7% from FY2020 to FY2025. However, net margin compressed from 6.0% in FY2021 to 2.7% in FY2025, and operating margin declined from 8.3% to 4.2%. Annual net income dropped from $17.29B in FY2021 and a peak of $22.38B in FY2023 to $12.06B in FY2025, with EPS falling to $16.31. For the trailing twelve months ending September 30, 2026, revenue stood at $450.06B with an operating margin of 5.8%. In the latest quarter, quarterly revenue fell 0.4% year-over-year while quarterly earnings expanded 75.9%.

As of September 30, 2026, UnitedHealth Group held $28.55B in cash and short-term investments against total debt of $74.33B, resulting in net debt of $45.78B. Shareholders' equity was $104.13B, with a debt-to-equity ratio of 0.71 and a current ratio of 0.74. For FY2025, the company generated $19.70B in operating cash flow and $16.07B in free cash flow. Capital allocation in FY2025 included $3.62B in capital expenditures, $5.54B in share buybacks, and $7.92B in dividends paid, contributing to a 5-year share count change of -5.5%.

UnitedHealth Group trades at a trailing P/E of 25.8x, below the 28.9x median of its S&P 500 Healthcare peers. Its forward P/E of 16.6x aligns closely with the peer median of 16.5x. The company's price-to-sales ratio of 0.8x and EV-to-EBITDA of 14.7x both sit below the peer medians of 3.4x and 15.7x, respectively. Over the trailing 1-year period, the stock gained 15.5%, trailing the 16.8% return of the S&P 500 (SPY). Over 5 years, the stock returned 2.6%, lagging the 83.0% return of the S&P 500 (SPY).

UnitedHealth Group pays an annual forward dividend of $9.28 per share, representing a dividend yield of 2.31% and a payout ratio of 38.8%. The company distributes dividends quarterly and has paid dividends for 37 consecutive years. Its 5-year annualized dividend growth rate is 12.6%, and its last ex-dividend date was September 14, 2026.

Wall Street coverage consists of 15 Strong Buy, 7 Buy, and 4 Hold ratings, with 0 Sell and 0 Strong Sell ratings. The mean price target of $477.04 represents an 18.8% upside relative to the last close of $401.43. For the fiscal year ending December 31, 2026, analysts estimate EPS of $20.51 and revenue of $448.67B. For the next fiscal year, 26 analysts project EPS of $23.23 on revenue of $463.78B. The company beat EPS estimates in 3 of the last 4 quarters.

This page is an AI-written research summary of UnitedHealth Group Incorporated (UNH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: UNH income statement, UNH balance sheet, UNH key metrics, UNH analyst forecast, UNH chart. See the UNH stock overview for the latest quote and news.